Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$130.67

-0.68 (-0.52%)

09:05
10/15/19
10/15
09:05
10/15/19
09:05

Johnson & Johnson says 2,000 sites now certified to treat patients with Spravato

Says: Continues to invest in R&D at competitive levels... Expects higher levels of investment in Q4... Sees FY19 effective tax rate 18%-18.5%... Sees Pharmaceutical division delivering FY20 sales above market... Sees FY20 tax rate similar to FY19 level... Sees FX a headwind in FY20, but less than FY19.

  • 15

    Oct

JNJ Johnson & Johnson
$130.67

-0.68 (-0.52%)

08/27/19
FBCO
08/27/19
NO CHANGE
Target $156
FBCO
Outperform
Opioid ruling reduces uncertainty, helps J&J move higher, says Credit Suisse
Credit Suisse analyst Matt Miksic notes that Johnson & Johnson appeared to react favorably to Oklahoma opioid ruling, due in part, to the $572M penalty being substantially lower than the $17B sought by State prosecutors. The analyst believes the decision helped reduce the range of uncertainty related to the potential opioid-related liability Johnson & Johnson could face, specifically in Oklahoma, if not across the U.S. more broadly. Miksic reiterates an Outperform rating and $156 target on the shares.
10/02/19
WELS
10/02/19
NO CHANGE
WELS
Outperform
J&J Ohio settlements suggest 'manageable' liability, says Wells Fargo
Wells Fargo analyst Larry Biegelsen notes that Johnson & Johnson has announced a settlement agreement with the Ohio counties of Cuyahoga and Summit that resolves all of the counties' claims with no admission of liability and removes the company from the federal trial scheduled to begin October 21, 2019 for a total of $20.4M. The analyst notes that after applying the total settlement amount to the populations of Cuyahoga and Summit counties and that to the total U.S. population of 327M, he arrives at a total settlement amount of $3.7B, which is well below his expected total settlement amount of $10B-$15B. Importantly, Biegelsen expects any settlement amount to be paid over a period of many years which will make the potential payments more manageable for Johnson & Johnson. He has an Outperform rating on the shares.
10/11/19
BERN
10/11/19
UPGRADE
BERN
Outperform
Johnson & Johnson upgraded to Outperform from Market Perform at Bernstein
10/11/19
BERN
10/11/19
UPGRADE
Target $155
BERN
Outperform
Bernstein upgrades 'historically cheap' Johnson & Johnson to Outperform
Bernstein analyst Lee Hambright upgraded Johnson & Johnson to Outperform from Market Perform with a price target of $155, up from $148. The shares in premarket trading are up $1.94, or 1.5%, to $131. The stock is "historically cheap," currently trading at a 17% discount to its sum-of-the-parts and a 13% discount to the S&P 500 Index, Hambright tells investors in a research note. The analyst, who believes J&J will resolve its legal liability for $10B-$12B, says the shares reflect a worst case scenario with $50B of liabilities being priced in. Following discussions with legal experts, Hambright has a "hard time seeing the worst-case scenarios playing out." The analyst estimates Johnson & Johnson faces about $5B of liability for opioids, another $5B for talc, and $800M for Risperdal.

TODAY'S FREE FLY STORIES

KB

KB Financial Group

$37.67

0.305 (0.82%)

, KR

Kroger

$26.75

-0.165 (-0.61%)

06:07
11/18/19
11/18
06:07
11/18/19
06:07
Upgrade
KB Financial Group, Kroger rating change  »

Correction: KB Financial,…

KB

KB Financial Group

$37.67

0.305 (0.82%)

KR

Kroger

$26.75

-0.165 (-0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNK

Teekay Tankers

$2.39

0.155 (6.94%)

06:06
11/18/19
11/18
06:06
11/18/19
06:06
Upgrade
Teekay Tankers rating change  »

Teekay Tankers upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELS

Equity Lifestyle

$69.44

0.795 (1.16%)

06:05
11/18/19
11/18
06:05
11/18/19
06:05
Upgrade
Equity Lifestyle rating change  »

Equity Lifestyle upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

MU

Micron

$47.70

0.88 (1.88%)

, WDC

Western Digital

$50.34

-0.03 (-0.06%)

06:05
11/18/19
11/18
06:05
11/18/19
06:05
Periodicals
U.S. to extend license allowing companies to do business with Huawei, NYT says »

The Trump administration…

MU

Micron

$47.70

0.88 (1.88%)

WDC

Western Digital

$50.34

-0.03 (-0.06%)

OCLR

Bought by LITE

$0.00

(0.00%)

ACIA

Acacia Communications

$67.08

0.58 (0.87%)

NPTN

NeoPhotonics

$8.57

0.08 (0.94%)

LITE

Lumentum

$68.91

0.91 (1.34%)

IIVI

II-VI

$29.45

0.19 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 03

    Dec

  • 09

    Dec

  • 09

    Dec

AVEO

Aveo Pharmaceuticals

$0.64

-0.0088 (-1.37%)

06:05
11/18/19
11/18
06:05
11/18/19
06:05
Hot Stocks
Aveo Pharmaceuticals presents new data from Phase 3 TIVO-3 trial of tivozanib »

AVEO Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$23.99

2.5 (11.63%)

06:05
11/18/19
11/18
06:05
11/18/19
06:05
Downgrade
Amarin rating change  »

Amarin downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

WRK

WestRock

$39.50

-0.52 (-1.30%)

06:04
11/18/19
11/18
06:04
11/18/19
06:04
Upgrade
WestRock rating change  »

WestRock upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JCOM

j2 Global

$95.90

1.17 (1.24%)

06:04
11/18/19
11/18
06:04
11/18/19
06:04
Initiation
j2 Global initiated  »

j2 Global initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 04

    Dec

  • 09

    Dec

ELS

Equity Lifestyle

$69.44

0.795 (1.16%)

06:03
11/18/19
11/18
06:03
11/18/19
06:03
Upgrade
Equity Lifestyle rating change  »

Equity Lifestyle upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

KRTX

Karuna Therapeutics

$17.26

-0.26 (-1.48%)

06:02
11/18/19
11/18
06:02
11/18/19
06:02
Hot Stocks
Karuna Therapeutics: KarXT met primary endpoint in Phase 2 trial »

Karuna Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGFEY

Eurobank

$0.00

(0.00%)

06:01
11/18/19
11/18
06:01
11/18/19
06:01
Upgrade
Eurobank rating change  »

Eurobank upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPLK

Splunk

$119.15

2.15 (1.84%)

06:01
11/18/19
11/18
06:01
11/18/19
06:01
Upgrade
Splunk rating change  »

Splunk upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CANG

Cango

$6.79

-0.05 (-0.73%)

06:00
11/18/19
11/18
06:00
11/18/19
06:00
Downgrade
Cango rating change  »

Cango downgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WDAY

Workday

$165.93

1.17 (0.71%)

06:00
11/18/19
11/18
06:00
11/18/19
06:00
Downgrade
Workday rating change  »

Workday downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

SFTBF

SoftBank

$0.00

(0.00%)

, SFTBY

SoftBank

$0.00

(0.00%)

06:00
11/18/19
11/18
06:00
11/18/19
06:00
Hot Stocks
SoftBank-backed Yahoo Japan set to merge with Naver's Line »

SoftBank Group announced…

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESTC

Elastic

$74.06

1.94 (2.69%)

05:59
11/18/19
11/18
05:59
11/18/19
05:59
Upgrade
Elastic rating change  »

Elastic upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

OKTA

Okta

$117.45

1.45 (1.25%)

05:59
11/18/19
11/18
05:59
11/18/19
05:59
Downgrade
Okta rating change  »

Okta downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 16

    Dec

NBGIF

National Bank of Greece

$0.00

(0.00%)

05:57
11/18/19
11/18
05:57
11/18/19
05:57
Upgrade
National Bank of Greece rating change  »

National Bank of Greece…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPIRD

Piraeus Bank

$0.00

(0.00%)

05:57
11/18/19
11/18
05:57
11/18/19
05:57
Upgrade
Piraeus Bank rating change  »

Piraeus Bank upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MUFG

Mitsubishi UFJ

$5.39

0.095 (1.79%)

05:56
11/18/19
11/18
05:56
11/18/19
05:56
Downgrade
Mitsubishi UFJ rating change  »

Mitsubishi UFJ downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ISSDY

ISS

$0.00

(0.00%)

05:55
11/18/19
11/18
05:55
11/18/19
05:55
Downgrade
ISS rating change  »

ISS downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMKBY

AP Moller Maersk

$0.00

(0.00%)

05:53
11/18/19
11/18
05:53
11/18/19
05:53
Downgrade
AP Moller Maersk rating change  »

AP Moller Maersk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMUS

T-Mobile

$78.05

1.18 (1.54%)

05:53
11/18/19
11/18
05:53
11/18/19
05:53
Conference/Events
T-Mobile to host business news update conference call »

Conference call to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 09

    Dec

BUD

AB InBev

$79.69

0.56 (0.71%)

05:52
11/18/19
11/18
05:52
11/18/19
05:52
Upgrade
AB InBev rating change  »

AB InBev upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

ADDYY

Adidas

$0.00

(0.00%)

05:52
11/18/19
11/18
05:52
11/18/19
05:52
Upgrade
Adidas rating change  »

Adidas upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.